Skip to main content

Market Overview

FibroGen Q4 Earnings Outlook


FibroGen (NASDAQ: FGEN) announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting FibroGen's loss per share to be near 29 cents on sales of $49.77 million.

FibroGen's loss in the same period a year ago was 50 cents per share and quarterly sales came in at $31.9 million. Analysts estimate would represent a 42 percent decrease in the company's earnings. Revenue would be up 55.96 percent on a year-over-year basis.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.37 -0.47 -0.62 -0.53
EPS Actual -0.5 -0.48 -0.52 -0.5


Stock Performance

Over the last 52-week period, shares are up 143.13 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with FibroGen. The strength of this rating has maintained conviction over the past three months. Most Common Rating: Neutral

Conference Call

FibroGen's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.


Related Articles (FGEN)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at